ArticleAmerican journal of cancer research2024

The modified melphalan and busulfan-based regimen combined with maintenance therapy improved the survival of patients with refractory/relapsed AML after allogeneic transplantation: middle-term outcome of a multicenter trial.

Shulian Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.